- Home
- MGNX vs GDO Comparison
MGNX vs GDO Comparison
Compare MGNX & GDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- GDO
- Stock Information
- Founded
- MGNX 2000
- GDO 2009
- Country
- MGNX United States
- GDO United States
- Employees
- MGNX N/A
- GDO N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- GDO Finance Companies
- Sector
- MGNX Health Care
- GDO Finance
- Exchange
- MGNX Nasdaq
- GDO Nasdaq
- Market Cap
- MGNX 70.3M
- GDO 82.4M
- IPO Year
- MGNX 2013
- GDO N/A
- Fundamental
- Price
- MGNX $1.26
- GDO $11.13
- Analyst Decision
- MGNX Hold
- GDO
- Analyst Count
- MGNX 10
- GDO 0
- Target Price
- MGNX $6.83
- GDO N/A
- AVG Volume (30 Days)
- MGNX 1.1M
- GDO 39.4K
- Earning Date
- MGNX 05-08-2025
- GDO 01-01-0001
- Dividend Yield
- MGNX N/A
- GDO 9.81%
- EPS Growth
- MGNX N/A
- GDO N/A
- EPS
- MGNX N/A
- GDO N/A
- Revenue
- MGNX $149,962,000.00
- GDO N/A
- Revenue This Year
- MGNX N/A
- GDO N/A
- Revenue Next Year
- MGNX $80.86
- GDO N/A
- P/E Ratio
- MGNX N/A
- GDO N/A
- Revenue Growth
- MGNX 155.26
- GDO N/A
- 52 Week Low
- MGNX $0.99
- GDO $11.21
- 52 Week High
- MGNX $17.24
- GDO $13.04
- Technical
- Relative Strength Index (RSI)
- MGNX 34.84
- GDO 48.51
- Support Level
- MGNX $1.10
- GDO $10.42
- Resistance Level
- MGNX $1.34
- GDO $11.03
- Average True Range (ATR)
- MGNX 0.13
- GDO 0.28
- MACD
- MGNX 0.04
- GDO -0.00
- Stochastic Oscillator
- MGNX 77.14
- GDO 62.69
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.